Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
ESC Heart Failure|December 24, 2024
Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE-HF and PRESERVED-HFAndrew P Ambrosy, Andrew J Sauer, Shachi Patel, et al.
JACC. Heart Failure|April 19, 2024
Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The PRESERVED-HF TrialSenthil Selvaraj, Shachi Patel, Andrew J Sauer, et al.
Circulation. Heart Failure|October 23, 2023
Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HFGregory D Lewis, Kensey Gosch, Laura P Cohen, et al.
Circulation. Heart Failure|May 19, 2023
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF TrialsMichael E Nassif, Sheryl L Windsor, Kensey Gosch, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trialMichael E Nassif, Sheryl L Windsor, Fengming Tang, et al.
JACC. Advances|June 27, 2025
Dapagliflozin's Association With Cardiorenal Outcomes and Apolipoprotein M Levels in HFrEF Patients: Insights From DEFINE-HFAndrew J Sauer, Joycie Chang, Zhuxuan Fu, et al.
Circulation|May 23, 2022
Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HFSenthil Selvaraj, Zhuxuan Fu, Philip Jones, et al.
Cardiovascular Diabetology|July 31, 2025
Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trialMohammad Abdel Jawad, Remo H M Furtado, Russell Esterline, et al.
Circulation. Heart Failure|October 18, 2024
Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection FractionSenthil Selvaraj, Shachi Patel, Andrew J Sauer, et al.
Circulation|September 17, 2019
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF TrialMichael E Nassif, Sheryl L Windsor, Fengming Tang, et al.
Pageof 5